ISRCTN10164855已完成1 期
A non-randomized, open-label, single-sequence, two-period phase I study to investigate the effect of CYP3A inhibition on the pharmacokinetics of RO6953958 in healthy participants
Roche (Switzerland)0 个研究点目标入组 16 人开始时间: 2021年11月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participants who are healthy as determined by medical evaluation including medical history, surgical history, physical examination, laboratory tests, and cardiac monitoring
- •2. Body mass index within the range 18 to 32 kg/m² (inclusive).
排除标准
- •1. Any condition or disease detected during the medical interview/physical examination that would render the participant unsuitable for the study, place the participant at undue risk, or interfere with the ability of the participant to complete the study, as determined by the investigator.
- •2. History or evidence of any medical condition potentially altering the absorption, metabolism, or elimination of drugs. This includes a surgical history of the gastrointestinal tract affecting gastric motility or altering the gastrointestinal tract.
- •3. History of any clinically significant gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, endocrinological, hematological, or allergic disease; unexplained syncope (within 12 months prior to screening); metabolic disorder; cancer; or cirrhosis.
- •4. Use of any psychoactive medication, or medications known to have effects on the CNS or blood flow, taken within 30 days prior to the first dosing (or within 5 times the elimination half-life of the medication) prior to the first dosing (whichever is longer).
- •5. History of convulsions (other than benign febrile convulsions of childhood), including epilepsy, or personal history of significant cerebral trauma or CNS infections (e.g., meningitis).
- •6. History of clinically significant hypersensitivity (e.g., drugs, excipients) or allergic reactions.
- •7. Any major illness within 1 month before the screening examination or any febrile illness within 1 week prior to screening and up to the first study drug administration.
- •8. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- •9. Known active infection or any major episode of infection within 4 weeks prior to the start of drug administration.
- •10. Participants who test positive for SARS-CoV-2 should not be enrolled.
- •11. Known hypersensitivity to itraconazole or to any of the other excipients, or to any other triazole antifungals.
- •12. Any other known contraindications to itraconazole as stated in the U.S. Prescribing Information.
- •13. Have used or intend to use over-the-counter (OTC or prescription medication including herbal medications as described in the list of prohibited medications.
- •14. Participants likely to need concomitant medication during the study period (including for dental conditions).
- •15. Positive result on hepatitis B or hepatitis C virus (HCV), presence of hepatitis B surface antigen (HBsAg), or positive hepatitis C antibody test result at screening or within 3 months prior to starting study treatment. NOTE: Participants with positive hepatitis C antibody test due to prior resolved disease can be enrolled if a confirmatory negative hepatitis C ribonucleic acid test is obtained.
- •16. A positive pregnancy test (women of childbearing potential only).
- •17. Positive test for drugs of abuse or alcohol.
- •18. Show evidence of human immunodeficiency virus (HIV) infection and/or positive test for HIV antibody at screening.
- •19. Dietary restrictions that would prohibit the consumption of standardized meals.
- •20. Participants who regularly smoke more than 5 cigarettes daily on average or vape equivalent amounts of nicotine and are unable or unwilling to stop smoking/vaping during the in-house period.
- •21. Only for the participants who will undergo taste assessment in Period 1: history or evidence of any medical condition that has altered taste sensory perception including age
研究者
相似试验
未知
1 期
DS-8500a midazolam DDI studyJPRN-jRCT2080222622DAIICHISANKYO Co.,Ltd.28
已完成
不适用
A randomized, open-label, two-period, two-sequence, single-dose, cross-over study to compare the pharmacokinetics, safety, and tolerability of the auto injector and pre-filled syringe of SB4 in healthy male subjects.NL-OMON45442Samsung Bioepis Co., Ltd.46
已完成
不适用
An open-label, randomized, two-period, two-sequence crossover, single-center trial to assess the bioequivalence of a single dose of 600 IU of freeze-dried r-hLH (Luveris®) versus a single 600 IU dose of the liquid formulation of Luveris® in the Pre-Filled Pen, administered subcutaneously (SC) in pituitary suppressed healthy premenopausal female subjects.vrouwelijke ovruchtbaarheidfemale infertilitypituitary hormone deficiencyNL-OMON37820Merck Sharp & Dohme (MSD)54
已完成
不适用
An Open Label, Randomized, 2-Sequence, Multiple-Dose Cross-Over Study to Investigate the Drug-Drug Interaction of Sevikar and Crestor in Healthy Adult VolunteersKCT0001058Daewoong Pharmaceutical32
进行中（未招募）
不适用
An open-label, non-randomized, sequential, multicenter study to evaluate the pharmacokinetics, efficacy and safety of once daily dosing compared to twice daily dosing of Orfadin in patients diagnosed with hereditary tyrosinemia type 1hereditary tyrosinemia type 1MedDRA version: 17.1Level: LLTClassification code 10069462Term: Tyrosinemia type ISystem Organ Class: 100000004850EUCTR2013-004132-29-DKSwedish Orphan Biovitrum AB (Publ)20